Want to see KLRS full AI Analyst Report?
KLRS Stock Chart & Stats
$6.32
--
Market closed
$6.32
--
Day’s Range― - ―
52-Week Range$2.14 - $11.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)136.22K
Market Cap
$95.60M
Enterprise Value$52.08M
Total Cash (Recent Filing)$97.22M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 19, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding23,792,278
10 Day Avg. Volume189,046
30 Day Avg. Volume136,224
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.60K
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$18.67Price Target Upside195.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation (TH103)Robust Phase 1a structural and functional gains, low systemic exposure and multi-month retreatment intervals suggest TH103 may offer durable efficacy and a favorable safety profile. This supports a differentiated product profile that can sustain competitive advantage through Phase 2/3 and into commercialization.
Low Financial LeverageVery low reported debt relative to equity reduces interest burden and short-term solvency risk for a cash-burning biotech. This balance-sheet position gives management flexibility to pursue equity raises, partnerships or milestone-based deals without immediate refinancing pressure over the next several months.
Strengthened Financial Leadership & GovernanceAdding an experienced biotech capital-markets CFO and maintaining audit/board continuity improves financial oversight, investor communication and strategic transaction capability. This reduces execution risk around financings and reporting during critical clinical development milestones.
Bears Say
Pre-revenue StatusAbsence of product revenue leaves operations entirely dependent on external capital and milestone events. Persistent pre-revenue status means even successful clinical readouts must be translated into funding or partnerships to sustain development, raising execution and timing risk over the medium term.
Significant Cash BurnHigh operating cash outflows require recurring financing to fund trials and operations. Although burn improved from 2024, sustained negative free cash flow increases likelihood of dilutive capital raises or strategic partnerships, which can delay programs and constrain optionality for management.
Eroding Equity And Weak Returns On EquityDeclining shareholders' equity and historically negative equity metrics reflect value erosion from ongoing losses. This history signals funding volatility and heightens the risk that future adverse clinical or market events will force dilutive financing, weakening stakeholder cushions over time.
Kalaris Therapeutics News
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $2.14 and its highest was $11.88 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $95.60M.
When is Kalaris Therapeutics’s upcoming earnings report date?
Kalaris Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on May 12, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.523 by $0.063.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate is -0.5.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 23,792,278 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.523. Following the earnings report the stock price went up 1.268%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kalaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (195.36% Upside)
$18.67 (195.36% Upside)
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.0%
Last 30 Days ▲ 19.4%
Last 30 Days ▲ 19.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.51%
Trailing 12-Months
Company Description
Kalaris Therapeutics
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
KLRS Stock 12 Month Forecast
Average Price Target
$18.67
▲(195.36% Upside)
Technical Analysis
Coherus Biosciences
―
Nektar Therapeutics
―
Cellectis SA
―
Seres Therapeutics
―
Kodiak Sciences
―
Ownership Overview
54.44% Insiders
1.98% Mutual Funds
4.37% Other Institutional Investors
38.07% Public Companies and
Individual Investors